IOVANCE Files 8-K for Simultaneous Communication Obligations

Ticker: IOVA · Form: 8-K · Filed: Jan 26, 2024 · CIK: 1425205

Iovance Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyIovance Biotherapeutics, Inc. (IOVA)
Form Type8-K
Filed DateJan 26, 2024
Risk Levelmedium
Pages1
Reading Time2 min
Key Dollar Amounts$0.000041666
Sentimentmixed

Complexity: simple

Sentiment: mixed

Topics: corporate-action, regulatory-filing, communication-rules

TL;DR

**IOVANCE just filed an 8-K indicating major corporate communications are underway, watch for big news!**

AI Summary

IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K on January 26, 2024, reporting an event that occurred on January 25, 2024. This filing indicates that the company is using this 8-K to simultaneously satisfy obligations under Rule 425, Rule 14a-12, Rule 14d-2(b), and Rule 13e-4(c), which are related to written communications, soliciting material, and pre-commencement communications. This matters to investors because it signals that Iovance is likely engaged in activities such as a merger, acquisition, or a significant offering, which could impact the stock price depending on the nature and terms of these communications.

Why It Matters

This filing suggests IOVANCE is involved in a significant corporate event requiring specific regulatory communications, which could lead to material news impacting its stock value.

Risk Assessment

Risk Level: medium — The filing itself doesn't detail the event, creating uncertainty about the nature and potential impact of the underlying corporate action.

Analyst Insight

Investors should monitor IOVANCE's news releases closely for upcoming announcements related to the corporate event hinted at by the simultaneous satisfaction of multiple communication rules, as this could significantly impact stock valuation.

Key Players & Entities

  • IOVANCE BIOTHERAPEUTICS, INC. (company) — the registrant filing the 8-K
  • January 25, 2024 (date) — date of the earliest event reported
  • January 26, 2024 (date) — date the 8-K was filed
  • Rule 425 (other) — Securities Act rule for written communications
  • Rule 14a-12 (other) — Exchange Act rule for soliciting material
  • Rule 14d-2(b) (other) — Exchange Act rule for pre-commencement communications
  • Rule 13e-4(c) (other) — Exchange Act rule for pre-commencement communications

Forward-Looking Statements

  • IOVANCE BIOTHERAPEUTICS, INC. will announce details of a significant corporate transaction (e.g., merger, acquisition, or major offering) within the next few weeks. (IOVANCE BIOTHERAPEUTICS, INC.) — medium confidence, target: 2024-02-29

FAQ

What is the primary purpose of this 8-K filing by IOVANCE BIOTHERAPEUTICS, INC.?

The primary purpose of this 8-K filing is to report an event that occurred on January 25, 2024, and to simultaneously satisfy filing obligations under Rule 425, Rule 14a-12, Rule 14d-2(b), and Rule 13e-4(c).

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 25, 2024.

Which specific SEC rules is IOVANCE BIOTHERAPEUTICS, INC. satisfying with this filing?

IOVANCE BIOTHERAPEUTICS, INC. is satisfying obligations under Rule 425 (Securities Act), Rule 14a-12 (Exchange Act), Rule 14d-2(b) (Exchange Act), and Rule 13e-4(c) (Exchange Act) with this filing.

What is the business address of IOVANCE BIOTHERAPEUTICS, INC. as stated in the filing?

The business address of IOVANCE BIOTHERAPEUTICS, INC. is 825 Industrial Road, Suite 400, San Carlos, California, 94070.

What is the Commission File Number for IOVANCE BIOTHERAPEUTICS, INC.?

The Commission File Number for IOVANCE BIOTHERAPEUTICS, INC. is 001-36860.

Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 9.8 · Accepted 2024-01-25 19:31:19

Key Financial Figures

  • $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke

Filing Documents

01

Item 8.01 Other Events. On January 25, 2024, Iovance Biotherapeutics, Inc. (the "Company") updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company's presentation that it intends to use at such events is attached as Exhibit 99.1 and incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Iovance Biotherapeutics, Inc., Corporate Presentation - January 25, 2024 104 Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 25, 2024 IOVANCE BIOTHERAPEUTICS, INC. By: /s/ Frederick G. Vogt Frederick G. Vogt, Interim CEO & General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.